Analysts See $-0.57 EPS for Intellia Therapeutics, Inc. (NTLA)

July 13, 2018 - By Peter Erickson

Analysts expect Intellia Therapeutics, Inc. (NASDAQ:NTLA) to report $-0.57 EPS on August, 7.They anticipate $0.12 EPS change or 26.67 % from last quarter’s $-0.45 EPS. After having $-0.51 EPS previously, Intellia Therapeutics, Inc.’s analysts see 11.76 % EPS growth. The stock increased 3.44% or $1.08 during the last trading session, reaching $32.47. About 547,568 shares traded. Intellia Therapeutics, Inc. (NASDAQ:NTLA) has risen 89.34% since July 13, 2017 and is uptrending. It has outperformed by 76.77% the S&P500.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company has market cap of $1.40 billion. The firm develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. It currently has negative earnings. The Company’s ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells.

More recent Intellia Therapeutics, Inc. (NASDAQ:NTLA) news were published by: Fool.com which released: “A Deep Dive Into the Latest CRISPR Controversy: Here’s What You Should Know” on July 04, 2018. Also Benzinga.com published the news titled: “Intellia Confirms Crispr Risk Irrelevant To Its Program, With No Adjustments Needed” on June 15, 2018. Nasdaq.com‘s news article titled: “CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of US Patent for CRISPR/Cas9 …” with publication date: June 19, 2018 was also an interesting one.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>